The clinical significance of cathepsin S expression in human astrocytomas.
about
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probesCathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization.RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma.Cathepsin S silencing induces apoptosis of human hepatocellular carcinoma cellsThe role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot studyAutophagy-Regulated ROS from Xanthine Oxidase Acts as an Early Effector for Triggering Late Mitochondria-Dependent Apoptosis in Cathepsin S-Targeted Tumor Cells.Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway.Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.Protease-activated drug development.Cysteine cathepsins in human cancer.Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and Treatment.Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis.Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation.Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinomaCathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors.Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosisEvaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer.Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways.Systematic review of protein biomarkers of invasive behavior in glioblastoma.Cysteine cathepsins and their potential in clinical therapy and biomarker discovery.CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness.Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: in vivo treatment and in vitro analysis.Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro.Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans.Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors.Developmentally regulated signaling pathways in glioma invasion.Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo.Cerebrospinal fluid cathepsin B and S.Cathepsin S expression: An independent prognostic factor in glioblastoma tumours--A pilot study.The regulation of cysteine cathepsins and cystatins in human gliomas.Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization.Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-mediated apoptosis through the induction of endoplasmic reticulum stress
P2860
Q26827307-807EA539-0241-4E93-AFC4-E98456000BF3Q33589216-6DD13755-04A2-4FE1-9993-18FDC0B30C1EQ34716082-5784182E-2657-476D-8AA7-842A70B6B015Q35137800-E48E9FBE-9BFE-43AF-9D1E-EACE3636843DQ35623073-4DADF1D8-05BD-4817-95F6-9F2BC959A4A2Q35647588-77AE8F90-6FF8-4F95-8726-4EA4FBF04464Q35670813-F38E575D-76E8-498B-A153-6E762AD0D95DQ35704154-AC7E9397-6940-4D79-AC84-EA9A83B58A02Q35811508-41D59916-C5D0-4B98-A1CB-E3B5ACF48761Q35970409-A2D6449E-631D-4B98-8C99-7FFE09C6337AQ35990061-8BC2B067-3244-4C50-B246-128A55E2C450Q36006105-44AC0739-885E-4765-A17F-882953CD2B15Q36400800-99B3244E-82B1-4354-8891-409ADC850D56Q36502706-46746C3F-0174-4F7C-8CA3-C166BC7EA7E9Q37076480-B8E69DD6-7465-4B1A-A484-3AF2DC0C7DD7Q37294866-706E7B85-04AB-4E4F-8EE7-B9833DB61C93Q37317502-10001F30-35B1-4DFE-9B05-9413B39AA084Q37715063-31ABB386-CDFC-482B-A062-7762D0F4AC11Q38165795-F19E35F5-B8A4-4198-8039-B66134DA22C8Q38182521-396D1A06-0484-408F-9A41-C954E6BE9BD6Q38286205-6196499E-761B-4361-BB3F-C3370AB4C60DQ38728647-E050CDFD-F12A-47A1-8D4C-CB9CD5EEC98DQ39202839-99BCDE3A-9887-4210-9FD1-C4D7998DBCEEQ39463194-2ECE74E7-2634-4856-B8C1-02E44A814D8DQ39852832-684834F7-A267-4BCE-907C-5772C5868FE0Q45264641-F65EFD8A-34BD-46CB-80EF-359DD78E6646Q46590926-AABA537A-8ABB-4667-93DF-1A7BEBD6B00AQ48148598-CC87536A-9254-486F-8511-91A7684C9457Q48191261-37BAD183-9294-49E0-9355-E577C7958FCBQ48601611-09BB0833-B4B0-4884-8E6C-85D570F516A5Q48610874-1DB40556-EAD2-4C64-A4B7-13557233B74EQ48686047-EE1C0F50-CF63-4EEA-8564-02D9A4E62924Q53109387-04685FFA-1EB0-4CEF-A0A8-4553F01E9F87Q58771027-B8C0F84F-631E-4120-8196-581B50F7E028
P2860
The clinical significance of cathepsin S expression in human astrocytomas.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The clinical significance of cathepsin S expression in human astrocytomas.
@en
The clinical significance of cathepsin S expression in human astrocytomas.
@nl
type
label
The clinical significance of cathepsin S expression in human astrocytomas.
@en
The clinical significance of cathepsin S expression in human astrocytomas.
@nl
prefLabel
The clinical significance of cathepsin S expression in human astrocytomas.
@en
The clinical significance of cathepsin S expression in human astrocytomas.
@nl
P2093
P2860
P1476
The clinical significance of cathepsin S expression in human astrocytomas
@en
P2093
Anne Trimble
Brian Walker
Caroline Greenan
Derek McCormick
Menakshi Mirakhur
Patrick G Johnston
Stephen McQuaid
Thomas Flannery
P2860
P304
P356
10.1016/S0002-9440(10)63641-3
P407
P577
2003-07-01T00:00:00Z